Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.

Apremilast is approved for the treatment of psoriasis and psoriatic arthritis. However, data on the efficacy and safety of apremilast in clinical practice are limited. We assessed the real-world use and effectiveness of apremilast in patients with moderate to severe plaque psoriasis visiting dermatologist practices in Belgium, from the perspectives of the patient and the physician. This prospective observational study enrolled adults aged 18 years or more initiating apremilast between 6 April 2017 and 30 June 2018, per Belgian reimbursement criteria. Primary outcome was the Patient Benefit Ind... Mehr ...

Verfasser: Ghislain, Pierre-Dominique
Lambert, Jo
Hoai, Xuãn-Lan Lam
Hillary, Tom
Roquet-Gravy, Pierre-Paul
de la Brassinne, Michel
Segaert, Siegfried
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Schlagwörter: Adolescent / Adult / Anti-Inflammatory Agents / Non-Steroidal / Belgium / Humans / Psoriasis / Quality of Life / Severity of Illness Index / Thalidomide / Treatment Outcome / Apremilast / Patient Benefit Index / Patient-reported outcomes
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26588351
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/263798